SuperworthKiniksa Pharmaceuticals International profit margin KNSA
Gross, operating and net profit as a share of revenue over the last twelve months, from 2022.
- Net margin, 12 months
- 9.6%
- Operating margin, 12 months
- 11.9%
- Net margin on a year earlier
- +8.7 pts
- Peer median
- 16.6%
Over the twelve months to Jun 30, 2026, Kiniksa Pharmaceuticals International kept 9.6% of its revenue as net profit, with an operating margin of 11.9% and a gross margin of 89.8%.
The median for 10 large drugmakers of a similar size is 16.6%.
Profit margin over time
Fiscal year by fiscal year
| Fiscal year | Net margin | Operating margin | Gross margin |
|---|---|---|---|
| FY2025 | 8.7% | 11.4% | 88.5% |
| FY2024 | −10.2% | −10.8% | 85.6% |
| FY2023 | 5.2% | −9.3% | 66.7% |
| FY2022 | 83.3% | 4.4% | 74.9% |
| FY2021 | n/a | n/a | n/a |
| FY2020 | n/a | n/a | n/a |
| FY2019 | n/a | n/a | n/a |
| FY2018 | n/a | n/a | n/a |
| FY2017 | n/a | n/a | n/a |
Quarter by quarter
| Quarter | Ended | Net margin, 12 months | Change on a year | Operating margin |
|---|---|---|---|---|
| Q2 FY26 | 9.6% | +8.7 pts | 11.9% | |
| Q1 FY26 | 9.7% | +13.2 pts | 12.4% | |
| Q4 FY25 | 8.7% | +18.9 pts | 11.4% | |
| Q3 FY25 | 6.0% | +8.4 pts | 6.4% | |
| Q2 FY25 | 0.9% | +3.9 pts | 0.8% | |
| Q1 FY25 | −3.5% | −6.4 pts | −3.3% | |
| Q4 FY24 | −10.2% | −15.4 pts | −10.8% | |
| Q3 FY24 | −2.4% | +0.3 pts | −6.8% | |
| Q2 FY24 | −3.0% | −85.4 pts | −8.1% | |
| Q1 FY24 | 2.9% | −80.2 pts | −10.1% | |
| Q4 FY23 | 5.2% | −78.1 pts | −9.3% | |
| Q3 FY23 | −2.7% | −83.2 pts | −7.7% |
Against its peers
Companies in Drug Manufacturers - General nearest Kiniksa Pharmaceuticals International's size, closest first, today.
| Company | Profit margin |
|---|---|
| KNSAKiniksa Pharmaceuticals International | 9.6% |
| LGNDLigand Pharmaceuticals | 67.9% |
| AMRXAmneal Pharmaceuticals | 5.0% |
| ALKSAlkermes plc. | 4.0% |
| TGTXTG Therapeutics | 55.2% |
| INDVIndivior Pharmaceuticals | 26.7% |
| PTGXProtagonist Therapeutics | 29.4% |
| ARQTArcutis Biotherapeutics | 6.1% |
| CORTCorcept Therapeutics | 6.6% |
| LQDALiquidia | 30.7% |
| OGNOrganon | 3.4% |
| Peer median | 16.6% |
Where Kiniksa Pharmaceuticals International ranks
What the profit margin tells you
Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).
Compare within an industry. 10% is superb for a retailer and poor for a software company.
More on Kiniksa Pharmaceuticals International
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.